Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL

NCT03666988 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03666988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03666988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
October 22, 2018
Completion date
March 4, 2021
Enrollment
31 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms